Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3233]

Study demonstrates drug combination is well tolerated, safe and effective for patients with aggressive blood cancer

Study demonstrates drug combination is well tolerated, safe and effective for patients with aggressive blood cancer

Understanding how a key protein helps aggressive blood cancer grow, paving the way for targeted therapies

Understanding how a key protein helps aggressive blood cancer grow, paving the way for targeted therapies

$FDA approves tafasitamab-cxix for relapsed or refractory follicular lymphoma$

FDA approves tafasitamab-cxix for relapsed or refractory follicular lymphoma

The role of fusion genes in cancer development and treatment

The role of fusion genes in cancer development and treatment

Unveiling cutting-edge advances in CAR-T cell therapy for lymphoma

Unveiling cutting-edge advances in CAR-T cell therapy for lymphoma

Food insecurity linked to elevated mortality risk among cancer survivors

Food insecurity linked to elevated mortality risk among cancer survivors

New review highlights bone health risks linked to modern cancer treatments

New review highlights bone health risks linked to modern cancer treatments

Fixed-duration acalabrutinib-based regimens approved in EU for patients with chronic lymphocytic leukaemia in the 1st-line setting

Fixed-duration acalabrutinib-based regimens approved in EU for patients with chronic lymphocytic leukaemia in the...

Thousands of blood cancer patients could benefit from new drug combination

Thousands of blood cancer patients could benefit from new drug combination

Genomic abnormalities in T-follicular helper lymphoma and patient outcomes

Genomic abnormalities in T-follicular helper lymphoma and patient outcomes

More from ecancer